We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

180 hedge funds and large institutions have $1.65B invested in Palvella Therapeutics in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 65 increasing their positions, 30 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more call options, than puts

Call options by funds: $53.5M | Put options by funds: $14.2M

210% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 21

117% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 30

61% more capital invested

Capital invested by funds: $1.02B → $1.65B (+$626M)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

29.57% more ownership

Funds ownership: 82.45% → 112.03% (+30%)

29% more funds holding

Funds holding: 140 → 180 (+40)

Holders
180
Holders Change
+40
Holders Change %
+28.57%
% of All Funds
2.22%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
65
Increased
65
Reduced
30
Closed
21
Calls
$53.5M
Puts
$14.2M
Net Calls
+$39.3M
Net Calls Change
+$29.3M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$41.6M
2
FCM
Frontier Capital Management
Massachusetts
+$39M
3
FLAM
First Light Asset Management
Minnesota
+$28.3M
4
SCM
Suvretta Capital Management
New York
+$27.2M
5
Jennison Associates
Jennison Associates
New York
+$26.4M

Top Sellers

1
SPPAM
Summit Partners Public Asset Management
Massachusetts
-$40.8M
2
PA
Perceptive Advisors
New York
-$27.9M
3
FAM
Fred Alger Management
New York
-$13.4M
4
Morgan Stanley
Morgan Stanley
New York
-$9.67M
5
SB
Samsara BioCapital
California
-$6.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
C
201
Covestor
United Kingdom
– +$104 +1 New
5 6 7 8
9

PVLA Hedge Fund Activity: Q1 2026 in Review

180 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2026, worth a combined $1.65B — up 61% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new PVLA positions and 21 closed out — a net gain of 44 holders — while 65 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $41.6M. The largest seller was Summit Partners Public Asset Management, exiting entirely with an estimated $40.8M sold.

  • 180 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2026, up from 140 in Q4 2025.
  • Funds reported $1.65B of Palvella Therapeutics stock for Q1 2026, up 61% quarter-over-quarter.
  • 65 funds opened new Palvella Therapeutics positions in Q1 2026 and 21 closed out, a net change of +44 holders.
  • The largest Palvella Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $41.6M added.
  • The largest Palvella Therapeutics seller in Q1 2026 was Summit Partners Public Asset Management, an estimated $40.8M sold.

Based on aggregated 13F filings for Q1 2026.